

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATIO	N NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/068,7	/51	11/02/1998	WOLFGANG-M. FRANZ	690-110PCT	2640	
2292	759	0 01/25/2005		EXAMINER		
BIRC	H STEW	ART KOLASCH &	ZARA, JANE J			
PO BO	X 747			· · · · · · · · · · · · · · · · · · ·		
FALL	S CHURC	H, VA 22040-0747	•	ART UNIT	PAPER NUMBER	
		•		1635	•	

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/068,751	FRANZ ET AL.					
Office Action Summary	Examiner	Art Unit					
	Jane Zara	1635					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on 28	October 2004.						
2a)☐ This action is FINAL . 2b)☒ Th	is action is non-final.						
3) Since this application is in condition for allow							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>83-124</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>83-124</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8)☐ Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on <u>28 October 2004</u> is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D 5) Notice of Informal F	ate Patent Application (PTO-152)					
3) ☑ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/06 Paper No(s)/Mail Date <u>44-47-94</u> .	6) Other:	atom representation (1.10-102)					
U.S. Patent and Trademark Office ///OZ/O2/ Office ///OZ/O2/	Action Summary Pa	art of Paper No./Mail Date 20050118					

DETAILED ACTION

This Office action is in response to the communication filed 10-28-04.

Claims 83-124 are pending in the instant application.

Response to Arguments and Amendments

Withdrawn Rejections

Any rejections not repeated in this Office action are hereby withdrawn.

New Rejections

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 83, 84, 86 -124 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 83, lines 7-9, it is unclear what is encompassed by "nucleotides of approximately residue –19 to approximately residue –800, with respect to the transcription starting point, which corresponds to nucleotide 2406 of SEQ ID NO: 1" (e.g. which residue corresponds to nucleotide 2406? Is it -19, -800 or somewhere between the two?). Appropriate clarification is required.

The metes and bounds of the term "corresponding to" cannot be determined (see e.g. claim 84, line 6; claim 91, lines 8, 10, 12, 16; claim 92, line 3; claim 93, lines 8, 10, 12 and 16). Appropriate clarification is required.

Application/Control Number: 09/068,751

Art Unit: 1635

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 83, 84, 86 -124 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to methods and compositions comprising a viral vector comprising a nucleic acid fragment of a mammalian myosin light chain-2 gene promoter comprising nucleotides corresponding to particular nucleotides of SEQ ID NO: 1 (e.g. claim 84, line 6; claim 91, lines 8, 10, 12, 16; claim 92, line 3; claim 93, lines 8, 10, 12 and 16).

The specification and claims do not indicate the distinguishing attributes concisely shared by the genus comprising a nucleic acid fragment of a mammalian myosin light chain-2 gene promoter comprising nucleotides *corresponding to* the particular nucleotide regions of SEQ ID NO:1 as listed in the claims. The disclosure does not clarify what common attributes are encompassed by this broad genus. The scope of the claims includes numerous structural variants (e.g. sequence variations encompassed by the term *corresponding to*) and the genus is highly variant because a significant number of structural differences between members of the genus are permitted. Concise structural features that could distinguish structures or compounds

Art Unit: 1635

within the genus encompassed by *corresponding sequences* are missing from the disclosure. No common structural attributes identify the members of this genus. The specification fails to teach or adequately describe a representative number of species in the genus such that the common attributes or characteristics concisely identifying members of the genus are exemplified. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus claimed. Thus, Applicant was not in possession of the claimed genus comprising a promoter fragment comprising nucleotide sequences *corresponding* to the various regions of SEQ ID NO: 1 set forth in the corresponding claims.

Maintained Rejections

Claim 85 is rejected under 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling, critical or essential to the practice of the invention, but not included in the claim(s) is not enabled by the disclosure for the same reasons of record set forth in the Office action mailed 10-30-03. See *In re Mayhew*, 527 F2d 1229, 188 USPQ 356 (CCPA 1976).

No arguments were made addressing this rejection for lacking a deposit of biological materials as set forth in the Office action mailed 10-30-03.

<u>Conclusion</u>

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices

published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is 703-872-9306. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (571) 272-0760. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).